Durvalumab-induced Immune-related Hepatitis in a Patient with Non-small Cell Lung Cancer-Reference-Cited by-同舟云学术

Durvalumab-induced Immune-related Hepatitis in a Patient with Non-small Cell Lung Cancer

Published:2020-11-01 Issue:21 Volume:59 Page:2711-2717
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Nakamura Masakatsu¹,Otsuka Toshimi¹,Hayashi Ranji¹,Horita Tomoe¹,Ota Masafumi¹,Sakurai Naoko¹,Takano Hikaru¹,Hayashi Tasuku¹,Kumagai Motona²,Yamada Sohsuke²,Arisawa Tomiyasu¹

Affiliation:

1. Department of Gastroenterology, Kanazawa Medical University, Japan

2. Department of Pathology and Laboratory Medicine, Kanazawa Medical University, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/59/21/59_4699-20/_pdf

Reference20 articles.

1. 1. Guidelines for medical treatment of lung cancer 2019 edition Japan Lung Cancer Society.

2. 2. Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stageIII non-small-cell lung cancer. N Engl J Med 377: 1919-1929, 2017.

3. 3. Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 379: 2342-2350, 2018.

4. 4. Osta B. El, Hu F, Sadak R, et al. Not all immune-checkpoint inhibitors are created equal: meta-analysis and systematic review of immune-related adverse events in cancer trials. Crit Rev Oncol Hematol 119: 1-12, 2017.

5. 5. Ribas A. Tumor immunotherapy directed at PD-1. N Engl J Med 366: 2517-2519, 2012.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hepatic Injury due to Drugs, Dietary and Herbal Supplements, Chemicals and Toxins;MacSween's Pathology of the Liver;2024

2. Immunotherapy in Elderly Patients Affected by Non-Small Cell Lung Cancer: A Narrative Review;Journal of Clinical Medicine;2023-02-24

3. Incidence rate and treatment strategy of immune checkpoint inhibitor mediated hepatotoxicity: A systematic review;Cancer Pathogenesis and Therapy;2023-01

4. Liver injury during durvalumab-based immunotherapy is associated with poorer patient survival: A retrospective analysis;Frontiers in Oncology;2022-10-24

5. Steatosis, Steatohepatitis and Cancer Immunotherapy: An Intricate Story;International Journal of Molecular Sciences;2021-11-30